News
Moderna has a deep pipeline of promising mRNA candidates that stand to boost business. Regeneron is looking at label ...
The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results